Guidance miss masks new products; monsoon-driven miss likely structural

Delivered revenue ₹742.5 Cr (₹72.5 Cr gap, 9.8% overstate), implied EBITDA ₹294 Cr

Q1 delivered -13.5%; full-year now expected negative/low single digit — 28.5pp miss

Confirmed in call; strong product mix improvement despite monsoon

Delivered OPM 39.6% on ₹742.5 Cr base, not 35% — management's 35% was on overstated ₹815 Cr

Prior: 15-20% growth. Q1: -13.5%. Full-year now tracking negative/low single digit — monsoon as primary cause, but regional concentration in South left company exposed vs peers.

New cotton 37% vs 22%, maize single-cross 20%+, paddy KRH7344/KRH7227 emerging. Shows R&D pipeline converting to revenue despite monsoon.

Now 15% vs prior 35% — price caps and illegal seed competition structural. Non-cotton now 80% of revenue, lower margin than historical 65% cotton base.

Prior 5-year ₹100 Cr target now 3 years. Q1 revenue 4x to ₹5.8 Cr; trial results in Philippines/Vietnam/Indonesia positive.

Madhya Pradesh acreage up 30%+ but Kaveri has no suitable hybrid — market lost to competitors. Maize -40% vs Bayer +20% shows structural weakness.

Mix shifted: cotton 90% in 2014-15 (high margin 35%) now only 20% (low margin 15%). New hybrids performing well; research encouraging. This monsoon year is one-off, not a benchmark.

Trialing complete in Philippines, Vietnam, Indonesia with good results. Sending material now, expect ₹100 Cr vegetables in coming time. 25%+ YoY growth rate.

Developed many hybrids in past 3-4 years; doubled in Northern India from small base. Illegal seeds and rain impacted Gujarat/Maharashtra. Inventory up ₹200 Cr vs prior year due to good-season expectations; will reduce production next year.

Don't have suitable hybrid product for Madhya Pradesh. Also weak in Maharashtra/Bihar. Regional product gap, not market-access issue.

Did 2,600 tonnes last year Kharif, only 1,500 this year — 1,100-1,200 tonne shortfall = ₹40-60 Cr sales. Confident we'll recover as monsoon improving.

Cost production 4-5% lower than last year vs realizations only 2-3% lower = margin advantage. This normalization + mix improvement = expansion. Gross margins up 2-3%.

Product mix shift underway. Cotton EBITDA fell 35% to 15% but shifting to non-cotton. Going forward, growth in both segments. Exports (₹100 Cr in 3 years) will be 25-30% margin.

Yes, maintaining 18-20% or 15-18% for next 2-3 years. Will recover with pipeline/launches. This year bad due to monsoon; mid/long term not worried.

Karnataka maize recovery (₹40-60 Cr), Rabi-heavy maize benefiting from higher prices (₹27-28 vs ₹16-17). No quantified full-year number given; implies full-year will be negative or low single digit.

Assumes new cotton/maize/paddy hybrids scale farmer adoption; export ₹100 Cr achieved; no monsoon repeat. No quantified base or order book. Pipeline unproven at scale.

Current 37.5% via 4-5% cost deflation and better mix. Next-year minimal production means cost normalization plateaus. New hybrids assumed to realize prices 2-3% lower than prior year near-term.

El Niño monsoon failure through June disrupted sowing. Company revenue -13.5% YoY, guidance miss 28.5pp. South India (Kaveri stronghold) particularly exposed — Karnataka 25-30% of prior Kharif sales. Repeat monsoon failure catastrophic.

New hybrids gaining share (cotton 37%, maize 20%+) but unproven in all regions. Madhya Pradesh acreage surged 30%+ but Kaveri has no suitable product — lost segment entirely. New hybrids need 2-3 years for farmer adoption. 10-year profit flat suggests execution challenges.

Lost 7-8 years cotton share; illegal seeds growing faster than legal hybrids despite new products. Government price caps limit margins (35% → 15% EBITDA). Competitors (Rasi, Bayer) still strong. Management confident but market share recovery unproven.

South (Karnataka, Andhra, Telangana) dominates Kharif; North (Bihar, UP) for Rabi. Kharif maize shortfall ₹40-60 Cr in Karnataka. Weak in Madhya Pradesh (lost growth market) and Maharashtra. Single-region shocks create large swings.

Maize -40% YoY while Bayer/Advanta +20%+ — 60pp performance gap shows structural disadvantage despite new products. Suggests product/distribution/farmer-preference gaps vs competitors.

₹200 Cr inventory buildup from good-season anticipation. Monsoon failed. Seed shelf-life constraints create potential write-off if new-product inventory doesn't sell. Working capital tied up.